| Cat.No. | Name | Information |
|---|---|---|
| M8975 | CWHM-12 | CWHM-12 is a potent inhibitor of αV integrins with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively. |
| M9173 | Cilengitide trifluoroacetate | Cilengitide is a potent integrin inhibitor for αvβ3 and αvβ5 receptor with IC50 of 4.1 nM, 79 nM in cell-free assays respectively. |
| M2042 | Cilengitide | Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. |
| M45152 | IDL-2965 | IDL-2965 is a small molecule heterocyclic compound that is also an inhibitor of αvβ1, αvβ3 , and αvβ6 for studies related to NAFLD and idiopathic pulmonary fibrosis. |
| M41632 | α7β1 integrin modulator-1 | α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. |
| M41631 | 3-Hydroxyxanthone | 3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one) is a xanthone compound, with . |
| M41630 | Orbofiban acetate | Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation. |
| M41629 | αvβ1 integrin-IN-2 | αvβ1 integrin-IN-2 is a potent inhibitor of integrins ανβ1 and α5β1 with IC50s of 0.9 nM, and 33 nM, respectively. |
| M41628 | Lotrafiban hydrochloride | Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease. |
| M41627 | REDV TFA | REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. |
| M41626 | Fradafiban hydrochloride | Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. |
| M31011 | Zalunfiban dihydrochloride | Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI). |
| M30942 | K34c | K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research. |
| M30902 | TC-I 15 | TC-I 15 (TC-I-15) is an allosteric, collagen-binding integrin α2β1 inhibitor with IC50 values of 26.8 μM and 0.4 μM for GFOGER and GLOGEN, respectively. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. |
| M30828 | BMS-688521 | BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model. |
| M30697 | EMD527040 | EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research. |
| M30656 | Valategrast hydrochloride | Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment. |
| M30472 | GPRP | GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa). |
| M30455 | JNJ-26076713 | JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization. |
| M30336 | Integrin Antagonists 27 | Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Target: Integrin in vitro: Integrin Antagonists 27 is treated with a panel of cancer cell-lines (breast cancer cell line MDA-MB-435, breast cancer cell lines MCF-7, mouse fibroblast NIH3T3, ovarian cancer cell line HEY, lung cancer cell line NCI-H1975) with all IC50 of >20 uM. |
| M30040 | Carotegrast | Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities. |
| M29750 | XVA143 | XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo. |
| M29738 | ATN-161 | ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
